礼来(LLY.US)涨超3%，报1073.76美元。消息面上，礼来旗下在研口服减肥药orforglipron在最新后期临床试验中取得关键进展。最新的临床数据显示，患者在从礼来的Zepbound或诺和诺德的Wegovy注射剂切换至orforglipron口服药后，能够维持绝大部分减重成果。礼来向美国食品药品监督管理局(FDA)提交了该每日一次GLP-1口服药的上市申请。(格隆汇)
礼来(LLY.US)涨超3%，报1073.76美元。消息面上，礼来旗下在研口服减肥药orforglipron在最新后期临床试验中取得关键进展。最新的临床数据显示，患者在从礼来的Zepbound或诺和诺德的Wegovy注射剂切换至orforglipron口服药后，能够维持绝大部分减重成果。礼来向美国食品药品监督管理局(FDA)提交了该每日一次GLP-1口服药的上市申请。(格隆汇)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.